Skip to main content
. Author manuscript; available in PMC: 2019 Aug 1.
Published in final edited form as: Stem Cells. 2018 Apr 22;36(8):1198–1209. doi: 10.1002/stem.2833

Figure 6. microRNAs activate TLR3.

Figure 6

(A) Neonatal cardiac fibroblasts were transfected with negmiR or miR combo. A mock transfection where lipid reagent alone was added to the cells was also used. The TLR3 inhibitor CU-CPT-4a, which interferes with RNA binding to TLR3, was added one day post-transfection. IL6 concentration in the media was assessed 4 days post-transfection and values expressed as pg IL6 per ug of total protein. N=4 independent experiments. Data represented as Mean ± SEM. Comparisons are made to the respective mock transfected group (*P<0.05, ns: not significant) and between negmiR and miR combo (†P<0.05).

(B) Neonatal cardiac fibroblasts were transfected with microRNAs (mock, miR combo) and siRNA (non-targeting control, TLR3, Ikbkb). IL6 concentration in the media was assessed 4 days post-transfection and values expressed as a ratio between miR combo and mock transfected cells. N=3 independent experiments. Data represented as Mean ± SEM. Comparisons are made to miR combo plus non-targeting control siRNA group, **P<0.01, *P<0.05.